Coverage
-
November 04, 2022
A Washington, D.C., federal judge has allowed the U.S. government to exit drugmaker Avadel's suit over the halted approval of narcolepsy medication Lumryz, finding that there are other avenues of relief available, such as related patent litigation that triggered the stay.
1 other articles on this case.
View all »